NCT00409435 A Study of Pyridostigmine in Postural Tachycardia Syndrome
| NCT ID | NCT00409435 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Mayo Clinic |
| Condition | Postural Tachycardia Syndrome |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2006-10 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 50 participants in total. It began in 2006-10 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a 3-day study comparing pyridostigmine versus placebo in the treatment of postural tachycardia syndrome (POTS). The researchers expect pyridostigmine to improve tachycardia and stabilize blood pressure.
Eligibility Criteria
Inclusion Criteria: Diagnosis of postural tachycardia syndrome using the following criteria: * Orthostatic heart rate increment greater than or equal to 30 beats per minute (bpm) within 5 minutes of head-up tilt. * Symptoms of orthostatic intolerance. These include weakness, lightheadedness, blurred vision, nausea, palpitations, and difficulty with concentration and thinking. Both criteria must be fulfilled. Exclusion Criteria: * Pregnant or lactating women * Presence of failure of other organ systems or systemic illness that could affect autonomic function or the patient's ability to cooperate with the study * Hypothyroidism or hyperthyroidism * Clinically significant coronary artery disease * Medications that could interfere with autonomic testing * Previous treatment with pyridostigmine for POTS. Patients must not have taken pyridostigmine in the past month
Contact & Investigator
Wolfgang Singer, M.D.
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT00409435 clinical trial?
This trial is open to participants of all sexes, aged 15 Years or older, up to 55 Years, studying Postural Tachycardia Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT00409435 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT00409435 currently recruiting?
Yes, NCT00409435 is actively recruiting participants. Visit ClinicalTrials.gov or contact Mayo Clinic to inquire about joining.
Where is the NCT00409435 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT00409435 clinical trial?
NCT00409435 is sponsored by Mayo Clinic. The principal investigator is Wolfgang Singer, M.D. at Mayo Clinic. The trial plans to enroll 50 participants.